Cargando…
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
Mucopolysaccharidoses type IIIA (MPS-IIIA) is a neurodegenerative lysosomal storage disorder (LSD) caused by inherited defects of the sulphamidase gene. Here, we used a systemic gene transfer approach to demonstrate the therapeutic efficacy of a chimeric sulphamidase, which was engineered by adding...
Autores principales: | Sorrentino, Nicolina Cristina, D'Orsi, Luca, Sambri, Irene, Nusco, Edoardo, Monaco, Ciro, Spampanato, Carmine, Polishchuk, Elena, Saccone, Paola, De Leonibus, Elvira, Ballabio, Andrea, Fraldi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662312/ https://www.ncbi.nlm.nih.gov/pubmed/23568409 http://dx.doi.org/10.1002/emmm.201202083 |
Ejemplares similares
-
Retinal Degeneration in MPS-IIIA Mouse Model
por: Intartaglia, Daniela, et al.
Publicado: (2020) -
Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2019) -
Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
por: Fraldi, Alessandro, et al.
Publicado: (2018) -
The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
por: Monaco, Antonio, et al.
Publicado: (2020) -
The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
por: Monaco, Antonio, et al.
Publicado: (2022)